These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9582604)

  • 1. CA 15-3 and bone scintigraphy in the follow-up of breast cancer.
    Younsi N; Montravers F; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
    Int J Biol Markers; 1997; 12(4):154-7. PubMed ID: 9582604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.
    Montravers F; Younsi N; Rousseau C; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
    Anticancer Res; 1997; 17(3B):1683-6. PubMed ID: 9179218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between bone scintigraphy and tumor markers in patients with breast cancer.
    Yildiz M; Oral B; Bozkurt M; Cobaner A
    Ann Nucl Med; 2004 Sep; 18(6):501-5. PubMed ID: 15515750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy.
    Nicolini A; Ferrari P; Sagripanti A; Carpi A
    Br J Cancer; 1999 Mar; 79(9-10):1443-7. PubMed ID: 10188888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
    Gedik GK; Kiratli PO; Tascioglu B; Aras T
    Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
    Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
    Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers?
    Buffaz PD; Gauchez AS; Caravel JP; Vuillez JP; Cura C; Agnius-Delord C; Fagret D
    Eur J Nucl Med; 1999 Jan; 26(1):8-11. PubMed ID: 9933655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reevaluaton of the usefulness of systematic bone scanning in initial staging and follow-up of small cell lung carcinoma, taking into account the serum levels of neuron-specific enolase.
    Gendreau V; Montravers F; Philippe C; Talbot JN
    Int J Biol Markers; 1997; 12(4):148-53. PubMed ID: 9582603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CA 15.3, CEA and ESR patterns in breast cancer.
    Rubach M; Szymendera JJ; Kamińska J; Kowalska M
    Int J Biol Markers; 1997; 12(4):168-73. PubMed ID: 9582607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma.
    Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Skopljak A
    Bosn J Basic Med Sci; 2006 Feb; 6(1):75-7. PubMed ID: 16533185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
    Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
    Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena.
    Yasasever V; Dinçer M; Camlica H; Karaloğlu D; Dalay N
    Clin Biochem; 1997 Feb; 30(1):53-6. PubMed ID: 9056110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations.
    Nicolini A; Carpi A; Ferrari P; Pieri L
    Tumour Biol; 2003; 24(6):275-80. PubMed ID: 15004486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Reliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastases].
    del Rocío Estrada-Sánchez G; Mireles Enríquez M; Valverde Castañeda N
    Rev Invest Clin; 2003; 55(4):412-8. PubMed ID: 14635605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use of tumor markers in the postoperative management of breast cancer patients: new concepts.
    Nicolini A; Carpi A; Ferrari P; Anselmi L
    Int J Biol Markers; 1997; 12(4):181-6. PubMed ID: 9582609
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.
    Molina R; Jo J; Zanón G; Filella X; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
    Br J Cancer; 1996 Oct; 74(7):1126-31. PubMed ID: 8855986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of bone alkaline phosphatase, CA 15-3 and CEA in the detection of bone metastases during the follow-up of patients suffering from breast carcinoma.
    Stieber P; Nagel D; Ritzke C; Rössler N; Kirsch CM; Eiermann W; Fateh-Moghadam A
    Eur J Clin Chem Clin Biochem; 1992 Dec; 30(12):809-14. PubMed ID: 1489855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
    Park BW; Oh JW; Kim JH; Park SH; Kim KS; Kim JH; Lee KS
    Ann Oncol; 2008 Apr; 19(4):675-81. PubMed ID: 18037623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of CEA for detection of distant metastases in newly diagnosed breast cancer: comparison with CA 15-3.
    Maccio G; Goussot V; Berriolo-Riedinger A; Riedinger JM
    Ann Biol Clin (Paris); 2017 Aug; 75(4):431-441. PubMed ID: 28751288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.